Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry

Rationale: Two antifibrotic medications, nintedanib and pirfenidone, have been approved for the treatment of idiopathic pulmonary fibrosis (IPF) in the United States. Few data have been published on the use of these medications in clinical practice. Objectives: To investigate patterns of use of anti...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ann Am Thorac Soc
Glavni autori: Salisbury, Margaret L., Conoscenti, Craig S., Culver, Daniel A., Yow, Eric, Neely, Megan L., Bender, Shaun, Hartmann, Nadine, Palmer, Scott M.
Format: Artigo
Jezik:Inglês
Izdano: American Thoracic Society 2020
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7640723/
https://ncbi.nlm.nih.gov/pubmed/32574517
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1513/AnnalsATS.201912-880OC
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items